Shiraz Transplant Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
Liver Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Arch Iran Med. 2018 Jul 1;21(7):275-282.
Iran's experience with liver transplantation (LT) began more than two decades ago. The purpose of this article is to present the status of LT in Iran, review specific characteristics of the programs, their outcomes, and their growth to become one of the largest LT programs in the world.
A questionnaire, asking for data on the number of transplants performed and specifics of the recipients and type of donors with focus on indications and outcomes was sent to LT programs.
During a period of 23 years, 4,485 LTs were performed at 6 centers in the country. Of these, 4106 were from deceased donors and 379 were from living donors. There were 3553 adults and 932 pediatric recipients. Hepatitis B and biliary atresia were the most common etiologies in adult and pediatric patients, respectively. Overall survival rates at 1, 5, and 10 years were 85%, 77%, and 71% for adults and 76%, 67% and 56% for pediatric patients, respectively.
Approval of the brain death law in Iran and coordinated efforts by the transplant centers to build comprehensive LT programs has resulted in the ability to procure more than 700 deceased donors per year with acceptable long-term survival.
伊朗的肝移植（LT）经验始于二十多年前。本文旨在介绍伊朗的 LT 现状，回顾该项目的具体特点、结果及其发展历程，使其成为世界上最大的 LT 项目之一。
我们向 LT 项目发送了一份问卷，要求提供已进行的移植数量以及受者和供者类型的详细信息，重点关注适应证和结果。
在 23 年的时间里，该国 6 个中心共进行了 4485 例 LT。其中，4106 例来自于已故供者，379 例来自于活体供者。有 3553 例成年受者和 932 例儿科受者。乙型肝炎和胆道闭锁分别是成年和儿科受者中最常见的病因。成人的 1 年、5 年和 10 年总生存率分别为 85%、77%和 71%，儿科患者分别为 76%、67%和 56%。
伊朗脑死亡法的批准以及移植中心的协调努力，建立了全面的 LT 项目，每年可获得 700 多名可接受的长期生存的已故供者。
